for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MannKind Corporation

MNKD.O

Latest Trade

2.08USD

Change

0.15(+7.77%)

Volume

4,857,576

Today's Range

1.92

 - 

2.08

52 Week Range

0.80

 - 

2.48

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.93
Open
1.93
Volume
4,857,576
3M AVG Volume
66.42
Today's High
2.08
Today's Low
1.92
52 Week High
2.48
52 Week Low
0.80
Shares Out (MIL)
229.17
Market Cap (MIL)
442.31
Forward P/E
-10.97
Dividend (Yield %)
--

Next Event

MannKind Corp at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual)

Latest Developments

More

MannKind Corp Unit Enters Into Amendment No. 2 To Credit And Security Agreement

MannKind Corp Reports Q2 Loss Per Share $0.05

MannKind Says Receives Forgivable Loan Under The Paycheck Protection Program

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About MannKind Corporation

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Industry

Biotechnology & Drugs

Contact Info

30930 Russell Ranch Rd Ste 300

WESTLAKE VILLAGE, CA

91362-7379

United States

+1.818.6615000

http://www.mannkindcorp.com

Executive Leadership

Kent Kresa

Independent Chairman of the Board

Michael E. Castagna

Chief Executive Officer, Director

Steven B. Binder

Chief Financial Officer

Stuart A. Tross

Chief People and Workplace Officer

David B. Thomson

Executive Vice President, General Counsel, Secretary

Key Stats

1.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.1K

2020(E)

0.1K
EPS (USD)

2017

-1.120

2018

-0.600

2019

-0.270

2020(E)

-0.176
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.14
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-222.94
Return on Equity (TTM)
-47.90

Latest News

Latest News

BRIEF-MannKind Presents Positive Original Analyses Of Afrezza Clinical Data

* MANNKIND PRESENTS POSITIVE ORIGINAL ANALYSES OF AFREZZA CLINICAL DATA AT AMERICAN DIABETES ASSOCIATION (ADA) 80TH SCIENTIFIC SESSIONS Source text for Eikon: Further company coverage:

BRIEF-MannKind Says Receives Forgivable Loan Under The Paycheck Protection Program

* MANNKIND RECEIVES FORGIVABLE LOAN UNDER THE PAYCHECK PROTECTION PROGRAM

BRIEF-Jennifer Grancio Appointed To MannKind Board Of Directors

* JENNIFER GRANCIO APPOINTED TO MANNKIND BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-MannKind Refocuses Pipeline Resources In Response To COVID-19 Pandemic

* MANNKIND REFOCUSES PIPELINE RESOURCES IN RESPONSE TO COVID-19 PANDEMIC

BRIEF-Mannkind Presents Novel Scientific Data At 13Th International Conference On Treatments For Diabetes

* MANNKIND - PRESENTS NOVEL SCIENTIFIC DATA AT 13TH INTERNATIONAL CONFERENCE ON ADVANCED TECHNOLOGIES & TREATMENTS FOR DIABETES Source text for Eikon: Further company coverage:

BRIEF-Mannkind Q1 Loss Per Share $0.25

* Q1 REVENUE ROSE 15 PERCENT TO $3.4 MILLION Source text for Eikon: Further company coverage:

BRIEF-Cipla Partners With Mannkind For Marketing, Distribution Of Afrezza In India

* PARTNERS WITH MANNKIND FOR EXCLUSIVE MARKETING, DISTRIBUTION OF AFREZZA IN INDIA

BRIEF-Mannkind And Cipla Enter An Exclusive Marketing And Distribution Agreement For Afrezza® In India

* MANNKIND AND CIPLA ENTER AN EXCLUSIVE MARKETING AND DISTRIBUTION AGREEMENT FOR AFREZZA® IN INDIA

BRIEF-Mannkind Announces $28.0 Million Registered Direct Offering

* MANNKIND ANNOUNCES $28.0 MILLION REGISTERED DIRECT OFFERING

BRIEF-MannKind Restructures $79.7 Mln Debt Obligation To The Mann Group

* MANNKIND RESTRUCTURES $79.7 MILLION DEBT OBLIGATION TO THE MANN GROUP AND REDUCES PRINCIPAL OWED TO DEERFIELD BY $6.3 MILLION

BRIEF-Mannkind Corporation Q4 Loss Per Share $0.28

* ORATION REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

BRIEF-David Kendall Joins MannKind As Chief Medical Officer

* MANNKIND CORP - MOST RECENTLY, KENDALL SERVED AS RESEARCH PHYSICIAN AND VICE PRESIDENT OF GLOBAL MEDICAL AFFAIRS FOR LILLY DIABETES Source text for Eikon: Further company coverage:

BRIEF-Mannkind, On Jan 18, Co, Unit Entered Into Exchange, Sixth Amendment To Facility Agreement With Deerfield

* MANNKIND - ON JAN 18, CO AND UNIT ENTERED INTO AN EXCHANGE AND SIXTH AMENDMENT TO FACILITY AGREEMENT WITH DEERFIELD - SEC FILING

BRIEF-Mannkind Q3 loss per share $0.31

* Mannkind Corporation reports 2017 third quarter financial results

BRIEF-Mannkind restructures near-term debt obligations

* Mannkind Corp - extended maturity of $10 million of deerfield facility to Jan 15, 2018 and allowed for such principal to be converted into common stock

BRIEF-Mannkind and Biomm submit registration dossier to Brazilian Health Regulatory Agency (anvisa)

* Mannkind and Biomm submit registration dossier to Brazilian Health Regulatory Agency (anvisa)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up